COVID-19 rapid guideline: delivery of systemic anticancer treatments [NG161], NICE (updated 12th February 2021)
The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | COVID-19 | Health | National Institute for Health and Clinical Excelle | Pandemics